Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | PTGES | O14684 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10160847 | 0.84 | CA12 (0.41) | CA12CA1CA2CA7CA9 | |
| SCHEMBL10196157 | 0.77 | THRA (0.40) | HPGDKDM4EMAPTCYP1A2CYP2C9 | |
| SCHEMBL10161344 | 0.76 | MAPT (0.51) | HPGDMAPTPKMHSD17B10ALDH1A1 | |
| SCHEMBL833170 | 0.74 | CA12 (0.53) | CA12CA1CA2CA7CA9 | |
| SCHEMBL10161418 | 0.73 | CYP3A4 (0.44) | CA12CA1CA2CA7CA9 | |
| SCHEMBL10160474 | 0.73 | TSHR (0.45) | CA12CA1CA2CA7CA9 | |
| SCHEMBL851838 | 0.73 | CA1 (0.61) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2662948 | 0.73 | CYP3A4 (0.62) | CA12CA1CA2CA7CA9 | |
| SCHEMBL28283411 | 0.73 | MEN1 (0.48) | CA12CA1CA2CA7CA9 | |
| SCHEMBL434350 | 0.73 | CA12 (0.47) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115819-A1 | Pentacycline Compounds | TETRAPHASE PHARMACEUTICALS, INC. | 2012-05-10 | — | — | US | disclosed |
| US-20120115819-A1 | Pentacycline Compounds | TETRAPHASE PHARMACEUTICALS, INC. | 2012-05-10 | — | — | US | disclosed |
| WO-2010132670-A2 | PENTACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115819-A1 | Pentacycline Compounds | TSLP, IL5, IL17A | CA12 1367/4885CA1 1430/4885CA2 651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.